CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed (NASDAQ: CRVO) announced that neflamapimod will be featured in two presentations at the 18th CTAD conference, Dec 1–4, 2025 in San Diego.
A late-breaking oral presentation on Dec 4, 2:10 p.m. PT will present full results from the Phase 2b RewinD-LB trial at 32 weeks, delivered by Prof. John-Paul Taylor. A poster (Poster 071) on Dec 1–2 reports that neflamapimod significantly lowers plasma GFAP and examines effects on NfL and Aβ42/40. Plasma assays were run at the Neurochemistry Laboratory, Amsterdam UMC under Prof. Charlotte Teunissen.
CervoMed (NASDAQ: CRVO) ha annunciato che neflamapimod sarà protagonista in due presentazioni alla 18ª conferenza CTAD, dal 1 al 4 dicembre 2025 a San Diego.
Una presentazione orale di aggiornamento il 4 dicembre alle 14:10 (PT) presenterà i risultati completi dello studio di fase 2b RewinD-LB a 32 settimane, a cura del Prof. John-Paul Taylor. Un poster (Poster 071) del 1–2 dicembre riporta che neflamapimod riduce significativamente il plasma GFAP e esamina gli effetti su NfL e Aβ42/40. Le analisi del plasma sono state eseguite presso Neurochemistry Laboratory, Amsterdam UMC, sotto la supervisione della Prof.ssa Charlotte Teunissen.
CervoMed (NASDAQ: CRVO) anunció que neflamapimod será presentado en dos ponencias en la 18ª conferencia CTAD, del 1 al 4 de diciembre de 2025 en San Diego.
Una ponencia oral de última hora el 4 de diciembre a las 14:10 hora del Pacífico presentará los resultados completos del ensayo de fase 2b RewinD-LB a las 32 semanas, a cargo del Prof. John-Paul Taylor. Un póster (Póster 071) del 1–2 de diciembre informa que neflamapimod reduce significativamente el plasma GFAP y examina efectos sobre NfL y Aβ42/40. Los ensayos plasmáticos se realizaron en el Neurochemistry Laboratory, Amsterdam UMC bajo la supervisión de la Prof. Charlotte Teunissen.
CervoMed (NASDAQ: CRVO)가 2025년 12월 1–4일 샌디에이고에서 열리는 제18차 CTAD 학회에서 neflamapimod가 두 편의 발표에 소개될 것이라고 발표했습니다.
12월 4일 오후 2시 10분(Pacific Time)에 열리는 늦은 발표에서 32주 차의 2b 단계 RewinD-LB 시험의 전체 결과가 John-Paul Taylor 교수에 의해 제시됩니다. 12월 1–2일의 포스터(포스터 071)는 neflamapimod이 혈장 GFAP를 유의하게 감소시키고 NfL 및 Aβ42/40에 대한 영향을 검토합니다. 혈장 분석은 Neurochemistry Laboratory, Amsterdam UMC에서 Ch. Teunissen 교수의 지휘 아래 수행되었습니다.
CervoMed (NASDAQ: CRVO) a annoncé que neflamapimod sera présenté dans deux communications lors de la 18e conférence CTAD, du 1er au 4 décembre 2025 à San Diego.
Une présentation orale de dernière minute le 4 décembre à 14 h 10 heure du Pacifique présentera les résultats complets de l’essai de phase 2b RewinD-LB à 32 semaines, présentée par le Prof. John-Paul Taylor. Un poster (Poster 071) du 1er au 2 décembre indique que le neflamapimod réduit significativement le plasma GFAP et examine les effets sur NfL et Aβ42/40. Les dosages plasmatiques ont été réalisés au Neurochemistry Laboratory, Amsterdam UMC sous la supervision de la Prof. Charlotte Teunissen.
CervoMed (NASDAQ: CRVO) gab bekannt, dass neflamapimod in zwei Präsentationen auf der 18. CTAD-Konferenz vorgestellt wird, vom 1. bis 4. Dezember 2025 in San Diego.
Eine späte mündliche Präsentation am 4. Dezember um 14:10 Uhr PT wird die vollständigen Ergebnisse der Phase-2b-RewinD-LB-Studie bei 32 Wochen präsentieren, vorgestellt von Prof. John-Paul Taylor. Ein Poster (Poster 071) vom 1.–2. Dezember berichtet, dass neflamapimod das plasma GFAP signifikant senkt und die Auswirkungen auf NfL und Aβ42/40 untersucht. Plasma-Analysen wurden im Neurochemistry Laboratory, Amsterdam UMC unter Leitung von Prof. Charlotte Teunissen durchgeführt.
CervoMed (NASDAQ: CRVO) أعلنت أن neflamapimod سيُعرض في عرضين تقديميين في المؤتمر CTAD الثامن عشر، من 1 إلى 4 ديسمبر 2025 في سان دييغو.
سيُقدم عرض شفهي متأخر في 4 ديسمبر الساعة 2:10 مساءً بتوقيت المحيط الهادئ النتائج الكاملة من تجربة المرحلة 2b RewinD-LB عند 32 أسبوعاً، بواسطة البروفسور جون-بول تايلور. بوستر (Poster 071) من 1–2 ديسمبر يشير إلى أن neflamapimod يخفض بنسب كبيرة GFAP في البلازما ويفحص الآثار على NfL وAβ42/40. التحاليل البلازمية أُجريت في Neurochemistry Laboratory، Amsterdam UMC تحت إشراف البروفسورة شارلوت تيونينسن.
- None.
- None.
Insights
Phase 2b results for neflamapimod in DLB are being presented, signalling meaningful clinical‑development progress.
Presentation of full Phase 2b RewinD‑LB results in a late‑breaking oral session by a lead investigator shows the program has reached a major public milestone. The company will present 32‑week treatment data at the CTAD meeting on
Key dependencies include the actual trial outcomes, statistical robustness, and peer review at the conference; the release notes claim clinical benefit but do not provide effect sizes or p‑values. Watch the oral presentation on
Biomarker data (GFAP, NfL, Aβ42/40) from RewinD‑LB are reported and could validate biological effect if analytic details hold up.
The poster highlights lowered plasma GFAP and correlations with clinical benefit, and reports analyses of plasma NfL and Aβ42/40 by an academic neurochemistry lab. Independent laboratory analysis under a named supervisor increases analytical credibility but the release omits assay methods, magnitude of change, and statistical thresholds.
Confirmatory items to watch are assay platforms, baseline and change values, correlation coefficients, and significance levels reported in the poster and oral slides at CTAD on
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB
New data demonstrating the utility of neflamapimod and its effects on key neurodegeneration biomarkers in DLB will also be highlighted in poster session
BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral, small molecule, targeting critical disease processes underlying degenerative disorders of the brain, will be featured in two presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place December 1-4, 2025, in San Diego, California.
In a late-breaking oral session by John-Paul Taylor, MBBS(hons) MRCPsych PhD, Professor of Translational Dementia Research at Newcastle University, United Kingdom (UK) and Chief Investigator of the RewinD-LB study for the UK, the full results of the Phase 2b RewinD-LB trial, including new data on the effects of neflamapimod treatment at 32 weeks, will be presented.
In addition, a poster presentation will highlight important findings from the RewinD-LB study regarding the utility of, and the treatment effects of neflamapimod on widely used neurodegeneration biomarkers in the trial, including plasma glial fibrillary acidic protein (GFAP), plasma neurofilament light chain (NfL), and beta amyloid 42/40 ratio. The plasma samples in the RewinD-LB study were analyzed by the Neurochemistry Laboratory at the Amsterdam University Medical Center (location Vrije Universiteit) under the supervision of Professor Charlotte Teunissen, PhD.
DLB is the second most common progressive dementia after Alzheimer’s disease (AD), affecting millions worldwide, and has no approved treatments. DLB progresses more rapidly than AD, with average time from diagnosis to requiring nursing home care being two years.
Neflamapimod Scientific Sessions
Late-Breaking Oral Session
Title: Results of the Phase 2b Trial of Neflamapimod in Dementia with Lewy Bodies
Session: LB31
Presenter: John-Paul Taylor
Authors: John-Paul Taylor, Stephen N Gomperts, Lawrence S Honig, Niels D Prins, Amanda Gardner, Kelly Blackburn, John Alam, James E Galvin
Date/Time: Thursday, December 4, 2:10 p.m. PT
Poster presentation
Title: Neflamapimod Significantly Lowers Plasma GFAP and Correlates with Clinical Benefit in Dementia with Lewy Bodies (DLB): Results from the RewinD-LB Trial
Session: Poster 071
Authors: John Alam, Hui-May Chu, Amanda Gardner, Kelly Blackburn, Charlotte E Teunissen
Date/Time: Monday, December 1 starting at 3:00 p.m. PT through Tuesday, December 2 at 5:30 p.m. PT
About the RewinD-LB Phase 2b Trial in Dementia with Lewy Bodies
The initial phase of RewinD-LB was a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in 159 participants with DLB, followed by a 32-week neflamapimod-only treatment extension phase. Patients with AD co-pathology, as assessed by plasma ptau181 levels, were excluded from the trial. The primary endpoint in the trial is change in the CDR-SB, and secondary endpoints include the ADCS-CGIC, the Timed Up and Go test, and a cognitive test battery.
The RewinD-LB trial was funded primarily by a
About Dementia with Lewy Bodies
DLB is the second most common progressive dementia after Alzheimer’s disease, affecting millions worldwide. Patients may experience a combination of decline in cognitive function, cognitive fluctuations, visual hallucinations, and sleep disorders, as well as motor symptoms similar to Parkinson’s disease. There are no approved treatments for DLB in the United States or European Union, and the current standard-of-care therapies only temporarily relieve symptoms.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral, small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026.
About Neflamapimod
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood–brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and frontotemporal dementia.
In non-clinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week open-label extension, further supported neflamapimod’s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing a positive effect on a key blood biomarker of neurodegeneration during the extension phase. Across both studies, the greatest benefits were observed in patients with “pure” DLB, those without AD co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.
Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic effects; the anticipated timing and achievement of clinical and development milestones, including the Company’s announcement of additional data or any meeting or correspondence between the Company and the FDA or other regulatory bodies; any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the RewinD-LB trial will be replicated in later trials, including the Company’s planned Phase 3 clinical trial evaluating the efficacy and safety of neflamapimod in patients with DLB; the timing of the initiation of and the design and endpoints of, any potential future trials, including the Company’s planned Phase 3 clinical trial evaluating the efficacy and safety of neflamapimod in patients with DLB; the Company’s need to acquire sufficient funding for any Phase 3 trial of neflamapimod in DLB; expectations with respect to neflamapimod, including the timing of any regulatory submissions and potential approvals thereof, if any; the timing of the Company’s potential submission of an NDA, if any; and the potential market for any DLB treatment that may be approved in the future. . Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “might,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.
Contacts
Media:
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
LifeSci Advisors
PJ Kelleher
Investors@cervomed.com
617-430-7579
FAQ
What will CervoMed (CRVO) present about neflamapimod at CTAD 2025?
When is the late-breaking oral presentation of the RewinD-LB Phase 2b results for CRVO at CTAD 2025?
What biomarkers will be reported for neflamapimod in the RewinD-LB trial (CRVO)?
Who is presenting the Phase 2b RewinD-LB results for CRVO at CTAD 2025?
Where were RewinD-LB plasma samples analyzed for the CRVO biomarker poster?
When and where will the neflamapimod poster for CRVO be available at CTAD 2025?
